FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial.

Emmanuelle Guérin,Lisa Belin,Guillaume Franchineau,Loïc Le Guennec,David Hajage,Mamadou Hassimiou Diallo,Thomas Frapard, Lucie Le Fèvre,Charles-Edouard Luyt,Alain Combes,Stéphane Germain,Jan Hayon,Pierre Asfar,Nicolas Bréchot

Critical care (London, England)（2023）

引用 0|浏览9

暂无评分

摘要

In this unique-dosing-regimen study, FX06 did not lower SARS-CoV-2-induced pulmonary vascular leakage. Future investigations will need to evaluate its efficacy at earlier times during the disease or using other regimens. Trial registration NCT04618042. Registered 5 November 2020.

查看译文

关键词

acute respiratory distress syndrome,sars-cov

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要